An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs BI 860585 (Primary) ; Exemestane; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 22 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2017 Planned End Date changed from 1 Oct 2016 to 30 Jul 2017.